Dyadic International Inc (DYAI) Actualités

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets

Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™...

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or...

Dyadic Expands Global Presence with Participation in Key Industry Events

JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”...

Form 8-K - Current report

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free...

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or...